5-Fluoro-2-methylbenzoic acid structure
|
Common Name | 5-Fluoro-2-methylbenzoic acid | ||
|---|---|---|---|---|
| CAS Number | 33184-16-6 | Molecular Weight | 154.138 | |
| Density | 1.3±0.1 g/cm3 | Boiling Point | 262.1±20.0 °C at 760 mmHg | |
| Molecular Formula | C8H7FO2 | Melting Point | 130-132 °C(lit.) | |
| MSDS | Chinese USA | Flash Point | 112.3±21.8 °C | |
| Symbol |
GHS07 |
Signal Word | Warning | |
| Name | 5-Fluoro-2-methylbenzoic acid |
|---|---|
| Synonym | More Synonyms |
| Density | 1.3±0.1 g/cm3 |
|---|---|
| Boiling Point | 262.1±20.0 °C at 760 mmHg |
| Melting Point | 130-132 °C(lit.) |
| Molecular Formula | C8H7FO2 |
| Molecular Weight | 154.138 |
| Flash Point | 112.3±21.8 °C |
| Exact Mass | 154.043015 |
| PSA | 37.30000 |
| LogP | 2.62 |
| Vapour Pressure | 0.0±0.6 mmHg at 25°C |
| Index of Refraction | 1.533 |
| Symbol |
GHS07 |
|---|---|
| Signal Word | Warning |
| Hazard Statements | H315-H319-H335 |
| Precautionary Statements | P261-P305 + P351 + P338 |
| Personal Protective Equipment | dust mask type N95 (US);Eyeshields;Gloves |
| Hazard Codes | Xi:Irritant; |
| Risk Phrases | R36/37/38 |
| Safety Phrases | S26-S37/39 |
| RIDADR | NONH for all modes of transport |
| WGK Germany | 3 |
| HS Code | 2916399090 |
|
~60%
5-Fluoro-2-meth... CAS#:33184-16-6 |
| Literature: ALANTOS PHARMACEUTICALS, INC. Patent: WO2006/116157 A2, 2006 ; Location in patent: Page/Page column 83 ; WO 2006/116157 A2 |
| Precursor 1 | |
|---|---|
| DownStream 10 | |
| HS Code | 2916399090 |
|---|---|
| Summary | 2916399090 other aromatic monocarboxylic acids, their anhydrides, halides, peroxides, peroxyacids and their derivatives VAT:17.0% Tax rebate rate:9.0% Supervision conditions:none MFN tariff:6.5% General tariff:30.0% |
|
Multkilogram Scale-Up of a Reductive Alkylation Route to a Novel PARP Inhibitor. Gillmore AT, et al.
Org. Process Res. Dev. 16(12) , 2063-72, (1999)
|
|
|
Design of HIV-1 integrase inhibitors targeting the catalytic domain as well as its interaction with LEDGF/p75: a scaffold hopping approach using salicylate and catechol groups.
Bioorg. Med. Chem. 19 , 4935, (2011) HIV-1 integrase (IN) is a validated therapeutic target for antiviral drug design. However, the emergence of viral strains resistant to clinically studied IN inhibitors demands the discovery of novel i... |
|
|
Structure-activity relationship of HIV-1 protease inhibitors containing alpha-hydroxy-beta-amino acids. Detailed study of P1 site.
Bioorg. Med. Chem. 7(9) , 2063-72, (1999) The structure-activity relationship of HIV-1 protease (HIV-1 PR) inhibitors containing alpha-hydroxy-beta-amino acids is discussed. We demonstrated that substituent groups on the P1 aromatic rings of ... |
| 3-Fluoro-6-methylbenzoic acid |
| 5-Fluoro-2-methylbenzoic acid |
| QVR CF F1 |
| 5-Fluoro-2-methyl-benzoic acid |
| 5-Fluor-2-methyl-benzoesaeure |
| Benzoic acid,5-fluoro-2-methyl |
| MFCD00042294 |
| Benzoic acid, 5-fluoro-2-methyl- |
| 2-methyl-5-fluorobenzoic acid |
| 5-Fluoro-o-toluic acid |
| 5-Fluoro-2-methyl benzoicacid |